Fidia SpA (FDA) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Fidia SpA €0.01, price €0.01, upside -26.7%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Fidia SpA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range €0.0034 – €243.00 · fair‑value band €0.0085 – €0.0094 · the €0.0116 price screens above the €0.0085 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Fidia SpA in your weekly email
Every Wednesday you see whether Fidia SpA is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems.
Show more
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. The company offers HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; pushbutton panels; XPower digital drives for axis and spindle movement; and I/O Line input/output modules. It also provides software solutions include ViMill, an anti-collision solution; Machine Monitor, a software to monitor NC variables and parameters; Velocity 6, a solution for axes control to enhance the performances of the machine; HiMill, a CAM software for the machining of dies, models, and aeronautical components; Isograph solution, a user interface; and procedure-PRX, a solution for customized automation. It serves automotive, aerospace, and power generation industries in Italy, Europe, Asia, North and South America, and internationally. The company was founded in 1974 and is headquartered in San Mauro Torinese, Italy.
Stock analysis
Fidia SpA (FDA) currently trades at €0.0116, while our model-based Fair Value estimate is €0.0085, 26.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €0.0100 per share, and 1 of the 7 models we run sit above the €0.0116 price.
Bear case: the DCF Models group reads lowest at €0.0100, and 6 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: €0.0085 (bear) to €0.0094 (bull), the price of €0.0116 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Industrials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Fidia SpA reported revenue of €31.1M in FY2025 versus €23.8M in FY2021, a compound +6.9%/yr. Reported net income was €1.0M in FY2025.
Key figures
Market cap €10.7M · P/S ratio 0.35 · Net margin 3.3% · Return on equity 18.3% · Return on assets (EBIT) −12.0% · Operating margin −3.3% · Revenue (TTM) €30.6M · Revenue growth (YoY) +125%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 95% below its 52-week high and 241% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −49% fair-value upside, at −27%, FDA screens cheaper than that median.
Fair Value models
Bear €0.0085Fair Value €0.0085Bull €0.0094
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.49/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+77.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Start year 2020 (pandemic). Over 10 years: −6.4% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−27.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−65.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−65.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−24% → −3%
⚠ Revenue per share shrinking 9.1%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Industrial Machinery · 782 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score42 · Bottom 25%
Fair Value upside−26.7% · Above median
Profitability
Return on equity (TTM)18.3% · Top 25%
Return on assets−3.9% · Bottom 25%
Net margin (TTM)3.4% · Below median
Operating margin (TTM)−3.3% · Bottom 25%
Growth and dividend
Revenue growth125.0% · Top 25%
Balance sheet
Debt / equity0.18× · Above median
Valuation Multiplesvs Specialty Industrial Machinery median · lower = cheaper
PEG1.06× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 30
PAST (return on equity)73· sector 28
HEALTH (low debt)91· sector 96
DIVIDEND (yield)0· sector 26
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Fidia SpA Fair Value". https://www.fairvalue-calculator.com/stock/FDA
Frequently asked questions
Is Fidia SpA (FDA) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of €0.0085 versus a price of €0.0116, about −27% upside (overvalued).
What is the fair value of FDA?
Our model-based fair value for Fidia SpA is €0.0085 (as of Sep 27, 2026), built from audited fundamentals. The current price: €0.0116.
What is the quality score of FDA?
Fidia SpA has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fidia SpA (FDA)?
Our model-based price target is the fair value of €0.0085 (as of Sep 27, 2026) from 8 valuation models. Cautious scenario €0.0085, optimistic scenario €0.0094. It is a calculation from audited fundamentals, not an analyst target.
What is the Fidia SpA stock forecast for 2026?
Our models put fair value at €0.0085, about −27% upside versus a price of €0.0116 (overvalued). Cautious scenario €0.0085, optimistic scenario €0.0094. The calculation is refreshed regularly with new filings.
What is the revenue of Fidia SpA (FDA)?
Fidia SpA reported trailing-twelve-month revenue of about €30.6M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Fidia SpA (FDA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fidia SpA it is €0.0085 per share (as of Sep 27, 2026), against a price of €0.0116. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Fidia SpA stock overvalued or undervalued in 2026?
As of Sep 27, 2026, FDA trades above its calculated fair value: price €0.0116, fair value €0.0085, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FDA?
No. The price is what the market pays today (€0.0116); the fair value is what the company's own numbers justify (€0.0085). For Fidia SpA the two are €0.0031 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fidia SpA worth?
The market values Fidia SpA at about €10.7M (market capitalisation, as of Sep 27, 2026). Per share that is €0.0116; our models calculate a fair value of €0.0085 per share.
What do the bullish and bearish scenarios say about FDA?
Our models span a range for Fidia SpA: cautious scenario €0.0085, base €0.0085, optimistic €0.0094 per share (as of Sep 27, 2026, price €0.0116). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of FDA?
The PEG ratio of Fidia SpA is 1.06 (P/E divided by earnings growth, as of Sep 27, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Fidia SpA (FDA)?
Balance-sheet figures for Fidia SpA (as of Sep 27, 2026): return on equity 18.3%, debt of 0.18 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is FDA from its 52-week high?
Fidia SpA trades at €0.0116, about 95% below its 52-week high of €0.2570 and 241% above the low of €0.0034 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €0.0085 is for.
Which stocks are comparable to Fidia SpA?
From the same area (Industrials) we also value GE Vernova Inc, SIE, Eaton Corporation, Parker-Hannifin Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fidia SpA stock attractive at the current price?
The data as of Sep 27, 2026: price €0.0116, calculated fair value €0.0085 (−27%), Quality Score 42/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FDA calculated?
We run Fidia SpA through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.0085, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Fidia SpA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fidia SpA (FDA)?
The closing price on Oct 2, 2026 was €0.0116. Our model-based fair value is €0.0085, about −27% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fidia SpA right now?
The price sits above even our optimistic bull case (€0.0094). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band (€0.0085 to €0.0094), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Fidia SpA
How large is the market capitalisation of Fidia SpA (FDA)?
The market capitalisation of Fidia SpA is €10.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fidia SpA (FDA)?
The price-to-sales ratio of Fidia SpA is 0.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Fidia SpA (FDA)?
The net margin of Fidia SpA is 3.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fidia SpA (FDA)?
The return on equity (ROE) of Fidia SpA is 18.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fidia SpA (FDA)?
On an EBIT basis the return on assets of Fidia SpA is −12.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fidia SpA (FDA)?
The operating margin of Fidia SpA is −3.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fidia SpA (FDA)?
Revenue at Fidia SpA is growing +125% versus a year earlier (3y avg +8.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fidia SpA (FDA)?
Earnings per share at Fidia SpA are growing −78.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Fidia SpA (FDA) generate?
The free cash flow of Fidia SpA is −€4.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Fidia SpA (FDA) carry?
The net debt of Fidia SpA is €1.0M (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Fidia SpA in the live analysis
One click puts Fidia SpA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
